Jpmorgan Chase & CO Regeneron Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 7,727,174 shares of REGN stock, worth $7.59 Billion. This represents 0.68% of its overall portfolio holdings.
Number of Shares
7,727,174
Previous 7,226,769
6.92%
Holding current value
$7.59 Billion
Previous $6.35 Billion
17.17%
% of portfolio
0.68%
Previous 0.66%
Shares
12 transactions
Others Institutions Holding REGN
# of Institutions
1,428Shares Held
82.1MCall Options Held
835KPut Options Held
1.46M-
Vanguard Group Inc Valley Forge, PA8.93MShares$8.77 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$8.42 Billion0.19% of portfolio
-
State Street Corp Boston, MA4.84MShares$4.76 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.65MShares$4.57 Billion0.76% of portfolio
-
Capital International Investors Los Angeles, CA3.13MShares$3.07 Billion0.62% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $105B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...